Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
- DOI
- 10.1016/s0140-6736(23)00620-7
- Published
- 2023 May 20
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-23-00620-7,
title = {Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.},
author = {Shitara K and Lordick F and Bang YJ and Enzinger P and Ilson D and Shah MA and Van Cutsem E and Xu RH and Aprile G and Xu J and Chao J and Pazo-Cid R and Kang YK and Yang J and Moran D and Bhattacharya P and Arozullah A and Park JW and Oh M and Ajani JA},
year = {2023},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(23)00620-7},
url = {https://doi.org/10.1016/s0140-6736(23)00620-7}
}RIS
TY - JOUR TI - Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. AU - Shitara K AU - Lordick F AU - Bang YJ AU - Enzinger P AU - Ilson D AU - Shah MA AU - Van Cutsem E AU - Xu RH AU - Aprile G AU - Xu J AU - Chao J AU - Pazo-Cid R AU - Kang YK AU - Yang J AU - Moran D AU - Bhattacharya P AU - Arozullah A AU - Park JW AU - Oh M AU - Ajani JA PY - 2023 JO - Lancet (London, England) DO - 10.1016/s0140-6736(23)00620-7 UR - https://doi.org/10.1016/s0140-6736(23)00620-7 ER -
APA
K, S., F, L., YJ, B., P, E., D, I., MA, S., E, V. C., RH, X., G, A., J, X., J, C., R, P., YK, K., J, Y., D, M., P, B., A, A., JW, P., M, O., & JA, A. (2023). Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(23)00620-7
Source records
- pubmed · retrieved 2026-09-26T22:48:11.487Z